Literature DB >> 1969173

Atypical neuroleptics suppress dopaminergic behavioral supersensitivity.

C Schremmer1, R Morgenstern, H Fink, T Ott.   

Abstract

Seven days after bilateral 6-OHDA denervation of the nucleus accumbens locomotor activity was recorded in rats. 6-OHDA lesion strongly enhanced hypermotility induced by apomorphine (1.0 mg/kg IP) as a sign of behavioral dopaminergic supersensitivity. The potency of the classical neuroleptic haloperidol (0.03-0.25 mg/kg IP) to antagonize apomorphine-induced hypermotility was reduced in 6-OHDA-pretreated rats. The atypical neuroleptics sulpiride (5.0-20.0 mg/kg IP), thioridazine (1.0-5.25 mg/kg IP) and clozapine (0.5-2.0 mg/kg IP) and the 5-HT antagonists cyproheptadine (0.2 mg/kg IP) and ritanserin (0.01 mg/kg IP) suppressed the augmented apomorphine response in 6-OHDA-lesioned animals to the level of the apomorphine effect in controls. It is concluded that the model of denervation supersensitivity is capable of differentiating typical and atypical neuroleptics. The abolition of the 6-OHDA-induced increase of the apomorphine hypermotility by the atypical neuroleptics cannot be explained solely by postsynaptic dopamine receptor antagonism. Serotonergic mechanism may be involved in this action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969173     DOI: 10.1007/bf02244614

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Dopamine-receptor binding and adenylate-cyclase activity in mouse striatal tissue in the supersensitivity phase after neuroleptic treatment.

Authors:  J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1978-12-08       Impact factor: 4.530

Review 3.  A systematic study of the pharmacological activities of dopamine antagonists.

Authors:  C J Niemegeers; P A Janssen
Journal:  Life Sci       Date:  1979-06-11       Impact factor: 5.037

4.  Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.

Authors:  D Dawbarn; C Pycock
Journal:  Eur J Pharmacol       Date:  1981-05-08       Impact factor: 4.432

5.  Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat.

Authors:  H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

6.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

Authors:  G R Breese; G E Duncan; T C Napier; S C Bondy; L C Iorio; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

7.  Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates.

Authors:  L Stinus; M Winnock; A E Kelley
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

9.  Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluorperazine for 15 months.

Authors:  N M Rupniak; S Boyce; P Jenner; C D Marsden
Journal:  Neuropharmacology       Date:  1984-08       Impact factor: 5.250

10.  Flumezapine, an antagonist of central dopamine and serotonin receptors.

Authors:  R W Fuller; N R Mason
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-10
View more
  3 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion.

Authors:  S Moore; P Kenyon
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.